医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

QIAGEN’s QuantiFERON-TB Gold Plus gains approval in Japan

2018年02月09日 AM06:05
このエントリーをはてなブックマークに追加


 

HILDEN, Germany & TOKYO

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining innovative CD4+/CD8+ design for comprehensive immune response detection with the most flexible blood collection workflow for efficient screening in large-scale TB control programs.

“QuantiFERON-TB Gold Plus sets a new global standard for latent TB testing. The proprietary CD4+/CD8+ T cell technology of QFT-Plus, with the addition of specific CD8+T cell stimulating antigens, has the potential to provide important insights for high-risk patients such as contacts exposed to active TB or HIV-positive persons,” said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. “In 2015, the Japanese government set a goal to reduce the country’s tuberculosis incidence rate to 10.0 per 100,000 persons by 2020. We are very happy to contribute to achievement of that goal with QFT-Plus becoming an important tool for use in Japan’s comprehensive TB control efforts.”

Japan’s approval of QFT-Plus follows 2017 approval in the United States and successful uptake of the test in more than 75 countries across Europe, the Middle East, Africa, Asia and Latin America, where nearly two million of the new tests have already been used. QFT-Plus builds on the foundation of QuantiFERON-TB Gold® (QFT®), the third generation of QIAGEN’s world-leading interferon gamma release assay (IGRA).

Please find the full press release here

(Link: https://corporate.qiagen.com/newsroom/press-releases/2018/20180208_QFT_Approval_Japan?sc_lang=en)

###

View source version on businesswire.com: http://www.businesswire.com/news/home/20180208006130/en/

CONTACT

QIAGEN
Investor Relations
John Gilardi
+49
2103 29 11711
e-mail: ir@QIAGEN.com
or
Public
Relations

Dr. Thomas Theuringer
+49 2103 29 11826
e-mail:
pr@QIAGEN.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc